Christopher Wilkins

Partner

Background

Christopher is a European and Chartered UK Patent Attorney. He joined Dehns in 2007 after completing an Honours degree in Molecular Biology and Biochemistry from Durham University and a PhD and research fellowship in Plant Molecular Biology at Cambridge University. He became an Associate of the firm in 2013, Senior Associate in 2019 and was made Partner in 2022.

 

Type of clients and client work

Clients include both large multinational companies and SMEs with various sizes of patent portfolios, and work includes evaluating inventions for patentability, drafting patent specifications and all aspects of patent prosecution, including worldwide prosecution of patent families. Christopher also provides advice on infringement and validity, opposition of granted patents and assistance with the development and management of patent portfolios.

 

Expertise

His work covers a wide range of biotechnology, medical and cosmetic fields. For instance, he has handled applications relating to: antibodies; artificial immune systems; pharmaceuticals, including peptide and protein based drugs; new medical uses of known biomolecules; virology and vaccination; newly identified genes and proteins and isolation methods; analyte detection methods and systems; genetically modified plants, animals and microorganisms; diagnostic assays; cosmetics; array technology; biofuel production; nucleic acid sequencing, amplification and identification; and molecular biology techniques.

 

Qualifications and Memberships

  • Authorised Representative before the Unified Patent Court (UPC) 2023
  • UK Chartered Patent Attorney, 2011
  • European Patent Attorney, 2011
  • Certificate in IP Law, University of London, 2009
  • Fellow of the Chartered Institute of Patent Attorneys
  • Member of the European Patent Institute
  • Member of the Royal Society of Biology
  • Basic Litigation Skills Course

 

Higher Education

BSc Hons Molecular Biology and Biochemistry, University of Durham, 2000

PhD, Plant Molecular Biology, University of Cambridge, 2004

Christopher was awarded his PhD in 2004 for research into the perception of the plant hormone cytokinin, and continued his research in this field as the ‘William Colton Fellow’ at Queens’ College, Cambridge University. During his fellowship he devoted a considerable amount of time to teaching, which included a lecture series in Plant and Microbial sciences for 2nd year undergraduates, as well as supervising undergraduate tutorial groups.

 

Other

Christopher has recently been recognised in the Patent 1000 IAM 2023 edition, with feedback from peers and clients noting: “Christopher (Kit) is an expert in cell therapy technologies and often has good ideas and insight on how to tweak and improve patent applications. Kit’s mastery of molecular details and the scope of applications greatly impresses. He immediately grasps what is most essential and thinks of all aspects of the filing under consideration. His grasp of both the European law and the biotechnologies is among the best in the business. His completes work swiftly, always on schedule and with excellent attention to detail. He is also capable of handling last-minute things and always to an excellent standard. He is a great person to work with. His demeanour and character are hyper-professional and extremely courteous. Kit can also handle EPO opposition work masterfully – his communication is detailed and timely, and includes multiple strategic options.”

Christopher frequently writes on the IP industry and the Life Sciences sector; see below for his articles.

Contact details

10 Old Bailey
London
EC4M 7NG
United Kingdom

+44 (0)20 7632 7200

Departments

biotechnology, consulting

Articles by Christopher Wilkins

Dehns named as “go-to firm for UK and EPO work” in the IAM Patent 1000 2023 edition Dehns named as “go-to firm for UK and EPO work” in the IAM Patent 1000 2023 edition 12 Jul 2023 4 min read CRISPR Patent Portfolio edited: The Broad Institute has lost its appeal on a key CRISPR patent in Europe CRISPR Patent Portfolio edited: The Broad Institute has lost its appeal on a key CRISPR patent in Europe 17 Jan 2020 5 min read CRISPR gene editing in a different class CRISPR gene editing in a different class 29 Nov 2019 4 min read Sight correction still needed for US diagnostic methods? Sight correction still needed for US diagnostic methods? 25 Nov 2019 5 min read Life (Sciences) at the Cutting Edge – Interesting times… Life (Sciences) at the Cutting Edge – Interesting times… 26 Sep 2018 4 min read 5 things I learned at the 5th Annual Peptides Congress 5 things I learned at the 5th Annual Peptides Congress 18 Apr 2018 4 min read Giving it away – how to protect your US patent Giving it away – how to protect your US patent 15 Sep 2017 6 min read The age of the “living drug” The age of the “living drug” 31 Aug 2017 2 min read Promises, promises…good news for patentees in Canada Promises, promises…good news for patentees in Canada 03 Jul 2017 4 min read A cheap way to revoke a UK patent? A cheap way to revoke a UK patent? 27 Apr 2017 5 min read A new growth area for GM crops? A new growth area for GM crops? 02 Feb 2017 3 min read A GM rose by any other name would smell as sweet (and won’t wilt) A GM rose by any other name would smell as sweet (and won’t wilt) 13 Jun 2016 3 min read How can we motivate companies to develop new antibiotics? How can we motivate companies to develop new antibiotics? 24 May 2016 3 min read How to patent diagnostic methods in the US How to patent diagnostic methods in the US 19 May 2016 3 min read A new treatment for type 2 diabetes and obesity? A new treatment for type 2 diabetes and obesity? 13 May 2016 3 min read New cancer therapies in the pipeline New cancer therapies in the pipeline 11 May 2016 3 min read Want an immune boost? Try worms… Want an immune boost? Try worms… 09 May 2016 2 min read UK BIA takes a strong stance on US patent law UK BIA takes a strong stance on US patent law 09 May 2016 3 min read Protection for Plant Varieties in Europe and the UK Post-Brexit Protection for Plant Varieties in Europe and the UK Post-Brexit 01 Aug 2022 9 min read